Black Diamond Therapeutics Announces Presentations at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
2024年4月25日 - 5:05AM
Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage
oncology company developing MasterKey therapies that target
families of oncogenic mutations in patients with cancer, today
announced forthcoming presentations during the 2024 ASCO Annual
Meeting, taking place May 31 – June 4 in Chicago, IL. The two
poster presentations describe data for BDTX-1535 in patients with
recurrent glioblastoma (GBM) across two clinical trials: a Phase 1
dose escalation trial, for which topline data were released in
December 2023, and a Phase 0/1 “trigger” (“window of opportunity”)
trial conducted as an Investigator Sponsored Trial at the Ivy Brain
Tumor Center (NCT06072586).
Presentation details are as follows:
Title: Phase 1 Study of BDTX-1535, an Oral
4th Generation Covalent EGFR Inhibitor, in Patients with Recurrent
Glioblastoma: Preliminary Dose Escalation
ResultsSpeaker/Author: Dr. Patrick Wen, Dana
Farber Cancer Institute and Harvard Medical SchoolDate and
Time: Saturday, June 1, 2024, 9:00 AM – 12:00 PM
CDTAbstract: 2068Poster: #367
Title: A Phase 0/1 ‘Trigger’ Trial of
BDTX-1535 in Recurrent High-Grade Glioma (HGG) Patients with EGFR
Alterations or Fusions Speaker/Author: Yoshie
Umemura, MD, BS, Ivy Brain Tumor Center and Barrow Neurological
Institute Date and Time: Saturday, June 1,
2024, 9:00 AM – 12:00 PM CDT Abstract: 2069
Poster: #368
Posters will become available on June 1, 2024 at
10:00 AM EDT on the Black Diamond Therapeutics website here.
About BDTX-1535BDTX-1535 is an
oral, brain-penetrant MasterKey inhibitor of oncogenic epidermal
growth factor receptor (EGFR) mutations in non-small cell lung
cancer (NSCLC), including classical driver mutations, non-classical
driver mutations, and the acquired resistance C797S mutation.
BDTX-1535 is a fourth-generation tyrosine kinase inhibitor (TKI)
that potently inhibits, based on preclinical data, more than 50
oncogenic EGFR mutations expressed across a diverse group of
patients with NSCLC in multiple lines of therapy. Based on
preclinical data, BDTX-1535 also inhibits EGFR extracellular domain
mutations and alterations commonly expressed in glioblastoma (GBM)
and avoids paradoxical activation observed with earlier generation
reversible TKIs. A “window of opportunity” trial of BDTX-1535 in
patients with GBM is ongoing (NCT06072586) and a Phase 2 trial is
ongoing in patients with NSCLC (NCT05256290).
About Black Diamond
TherapeuticsBlack Diamond Therapeutics is a clinical-stage
oncology company focused on the development of MasterKey therapies
that address families of oncogenic mutations in clinically
validated targets. The Company’s MasterKey therapies are designed
to address broad genetically defined patient populations, overcome
resistance, minimize wild-type mediated toxicities, and be brain
penetrant to treat CNS disease. The Company is advancing two
clinical-stage programs: BDTX-1535, a brain-penetrant
fourth-generation EGFR MasterKey inhibitor targeting EGFR mutant
NSCLC and GBM, and BDTX-4933, a brain-penetrant RAF MasterKey
inhibitor targeting KRAS, NRAS and BRAF alterations in solid
tumors. For more information, please visit
www.blackdiamondtherapeutics.com.
Forward-Looking
StatementsStatements contained in this press release
regarding matters that are not historical facts are
“forward-looking statements” within the meaning of the Private
Securities Litigation Reform Act of 1995. Because such statements
are subject to risks and uncertainties, actual results may differ
materially from those expressed or implied by such forward-looking
statements. Any forward-looking statements in this statement are
based on management’s current expectations of future events and are
subject to a number of risks and uncertainties that could cause
actual results to differ materially and adversely from those set
forth in or implied by such forward-looking statements. Risks that
contribute to the uncertain nature of the forward-looking
statements include those risks and uncertainties set forth in its
Annual Report on Form 10-K for the year ended December 31, 2023,
filed with the United States Securities and Exchange Commission and
in its subsequent filings filed with the United States Securities
and Exchange Commission. All forward-looking statements contained
in this press release speak only as of the date on which they were
made. The Company undertakes no obligation to update such
statements to reflect events that occur or circumstances that exist
after the date on which they were made.
Contacts
For Investors:Mario Corso, Head of Investor
Relations, Black Diamond Therapeuticsmcorso@bdtx.com
For Media:media@bdtx.com
Black Diamond Therapeutics (NASDAQ:BDTX)
過去 株価チャート
から 4 2024 まで 5 2024
Black Diamond Therapeutics (NASDAQ:BDTX)
過去 株価チャート
から 5 2023 まで 5 2024